News

March 8, 2016March 8, 2016

Allergic Asthma Patients Show Improvement by Adding Spiriva Respimat to Therapy, According to New Analyses of Data

Asthma, News

Boehringer Ingelheim Pharmaceuticals recently announced that adding its soft mist inhaler device Spiriva Respimat to deliver asthma maintenance drugs helps patients with allergic asthma better control their symptoms. The findings were presented at the ... Read more

March 8, 2016May 13, 2016

Lung Institute Opens Stem Cell Therapy Clinic in Dallas for Patients with Chronic Lung Diseases

COPD, Idiopathic Pulmonary Fibrosis, News

A top provider of stem cell therapy research for lung conditions, the Lung Institute, recently announced its new location, close to the metro Dallas area in Texas. The Institute has also ... Read more

March 7, 2016March 7, 2016

Therabron Announces New Program to Enhance Lung Health at 2016 Conference

COPD, News

Therabron Therapeutics recently presented a study titled “Modification of CC10 Protein by Reactive Oxygen Species (ROS) during Acute Lung Injury” that introduces a program designed to develop several novel isoforms of ... Read more

March 7, 2016March 7, 2016

Two Phase 3 Trials for Asthma Drug Lebrikizumab Have Differing Results, Genentech Reports

Asthma, News

Genentech, a member of the Roche Group, recently reported top-line data from two Phase 3 clinical trials assessing the efficacy and safety of lebrikizumab in people with uncontrolled asthma despite ... Read more

March 7, 2016March 16, 2016

Savara Preparing Clinical Trial on Lung Infection Therapy for CF After Completing $20M Round of Financing

Cystic Fibrosis, News

Austin, Texas-based Savara Pharmaceuticals, a company focused on novel drugs for the treatment of rare respiratory diseases, recently announced the completion of a $20 million Series C round of financing. The ... Read more

March 4, 2016March 4, 2016

Actelion Emphasizes Commitment to Patients on Rare Disease Day

News, Pulmonary Hypertension

The theme of Rare Disease Day 2016, “Patient Voice — Join us in making the voice of rare diseases heard,” was a major cause for Switzerland-based Actelion, a leader in the field ... Read more

March 4, 2016March 4, 2016

Genentech’s Application of Xolair for Allergic Asthma in Kids Is Under FDA Review

Asthma, News

Genentech recently announced that its supplemental Biologics License Application (sBLA) for extension of Xolair (omalizumab) in allergic asthma in pediatric patients has been accepted by the U.S. Food and Drug Administration (FDA). ... Read more

March 4, 2016March 16, 2016

IPF Patient Survey Reveals Fear, Worry Most Commonly Experienced Emotions When Diagnosed

Idiopathic Pulmonary Fibrosis, News

An international online survey with more than 500 participants suffering from idiopathic pulmonary fibrosis (IPF) provided a picture into the real-life emotions of these patients. The survey was conducted by Germany-based Boehringer Ingelheim ... Read more

March 3, 2016March 16, 2016

Key Cause of Pulmonary Fibrosis May Be Linked to Harmful Macrophages

Idiopathic Pulmonary Fibrosis, News

Researchers at the University of Alabama at Birmingham (UAB) published a new report linking macrophages to pulmonary fibrosis (PF). Macrophages are cells that engulf toxins and harmful molecules, but in pulmonary ... Read more

March 3, 2016March 3, 2016

Advanced Squamous Cell Lung Cancer Drug Giotrif Gets Thumbs-Up from EMA’s Committee for Medicinal Products

Lung Cancer, News

Boehringer Ingelheim announced a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the company’s product Giotrif (afatinib) for the treatment of advanced squamous cell ... Read more